Breaking News

You are here » Indian-Commodity  :  Top News  :  Lupin's JV completes global Phase III clinical trial of Etanercept biosimilar

08-Feb2018

Lupin's JV completes global Phase III clinical trial of Etanercept biosimilar

Lupin's joint venture (JV) YL Biologics (YLB) has successfully completed global Phase III clinical trial of its investigational Etanercept biosimilar (YLB113). The Phase III study of YLB113 was a multinational randomized double-blind controlled trial of 52 weeks duration which included more than 500 patients with rheumatoid arthritis (RA) in 11 countries. It compared YLB113's efficacy and safety directly against Enbrel (of Amgen/Pfizer) which has a global market of $11 billion (IQVIA MAT Q3 2017), and is a widely successful biologic agent globally used for the treatment of multiple autoimmune disorders including RA. YLB is a joint venture between the company and Yoshindo in Japan.

The primary endpoint was an equivalent improvement in the rheumatoid arthritis, as measured by American College of Rheumatology 20 (ACR20) response rate. The ACR20 response rate of YLB113 has been found to be within a pre-defined equivalence margin that is expected by most advanced regulatory agencies for marketing authorization. In addition, safety and immunogenicity (antibody formation) of YLB113 was also found to be similar to Enbrel indicating therapeutic equivalence.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.


Related News

View all news

Physical rubber prices ruled steady on Saturday

Physical Rubber prices ruled steady on Saturday due to buyer resistance in the market. Spot prices for RSS-4 and RSS-5 variety closed unchanged at Rs 125/ kg and Rs 120.50/ kg respectively.In the futures......

Gold futures trade almost steady on Monday

Gold futures traded almost steady on Monday, with cautious outlook from investors as they eyed on impending report from china showcasing dimmed economic growth to its slowest in 28 years in 2018 in face......

Crude palm oil futures trade in green on rise in demand

Crude palm oil futures traded in green on MCX in line with the firm  trend in Malaysian palm oil prices. Moreover, rise in spot demand from domestic markets coupled with the worries on dip in......

Top News

View all news

Glenmark Pharma recalling 96,240 applicators of its product from US

Glenmark Pharmaceuticals is recalling 96,240 applicators of its product Estradiol vaginal inserts for defective delivery system. The USFDA has termed it as a Class-II recall. The USFDA has classified Class-II......

Infosys hires over 7,600 staff in US

Infosys has hired over 7,600 staff in the US. This hiring is more than three-fourth of its target of recruiting 10,000 American workers. The company is making recruitment from local schools a 'sustained......

SBI to sell 26% stake of SBI payment services

State Bank of India (SBI) is planning to sell 26% stake of its SBI payment services (SPSPL) to Hitachi Payment Services (HPY). After allotment of the shares, SBI shareholding in SPSPL will become 74% from......